Targeted molecular therapeutics for bladder cancer—a new option beyond the mixed fortunes of immune checkpoint inhibitors?
O Bednova, JV Leyton - International journal of molecular sciences, 2020 - mdpi.com
The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies
approved since 2016 that target programmed cell death protein 1 or programmed death …
approved since 2016 that target programmed cell death protein 1 or programmed death …
The Financial Burden of Localized and Metastatic Bladder Cancer
Background and objective Bladder cancer (BCa) imposes a substantial economic burden on
health care systems and patients. Understanding these financial implications is crucial for …
health care systems and patients. Understanding these financial implications is crucial for …
Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression
Z Yang, Y Zheng, H Wu, H Xie, J Zhao, Z Chen, L Li… - Human Genomics, 2023 - Springer
Abstract Background Super-enhancers (SEs), driving high-level expression of genes with
tumor-promoting functions, have been investigated recently. However, the roles of super …
tumor-promoting functions, have been investigated recently. However, the roles of super …
Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment
Y Lu, Z Dai, F Chang, L Wang, J He, P Shi, H Zhang… - …, 2023 - Springer
Background The disutilities of adverse events (AEs) are important inputs for cost-utility
analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology …
analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology …
Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non–Muscle Invasive Bladder …
M Joshi, SJ Atlas, M Beinfeld, RH Chapman, DM Rind… - Value in Health, 2023 - Elsevier
Objectives Nadofaragene firadenovec is a gene therapy for bacillus Calmette-Guérin (BCG)–
unresponsive non–muscle-invasive bladder cancer (NMIBC) undergoing Food and Drug …
unresponsive non–muscle-invasive bladder cancer (NMIBC) undergoing Food and Drug …
[PDF][PDF] A novel nine-lncRNA risk signature correlates with immunotherapy in hepatocellular carcinoma
Y Nie, J Li, W Wu, D Guo, X Lei, T Zhang… - Frontiers in …, 2021 - frontiersin.org
Background Hepatocellular carcinoma is one of the most common malignant tumors with a
very high mortality rate. The emergence of immunotherapy has brought hope for the cure of …
very high mortality rate. The emergence of immunotherapy has brought hope for the cure of …
Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
LY Yang, JR Li, CS Chen, CL Cheng… - Frontiers in …, 2024 - frontiersin.org
Objectives: Immune checkpoint inhibitor (ICI) is an important treatment option for metastatic
urothelial carcinoma (mUC) patients. A lot of clinical evidence proved the survival benefits of …
urothelial carcinoma (mUC) patients. A lot of clinical evidence proved the survival benefits of …
[HTML][HTML] The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma: a literature review of practice-changing trials
SH Song, JJ Oh - Journal of Urologic Oncology, 2023 - e-juo.org
Traditional cisplatin-based chemotherapy has long been the mainstay treatment for
advanced urothelial carcinoma (UC), but the emergence of immune checkpoint inhibitors …
advanced urothelial carcinoma (UC), but the emergence of immune checkpoint inhibitors …
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: a …
M Beinfeld, SJ Atlas, D Touchette, A McKenna… - Journal of Managed …, 2021 - jmcp.org
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California
Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and …
Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and …
Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis
Y Lang, Y Lin, D Li, J Liu, X Liu - Cancer Medicine, 2023 - Wiley Online Library
Purpose The KEYNOTE‐062 trial demonstrated the efficacy and safety of pembrolizumab for
advanced gastric cancer (GC). The current study evaluated the cost‐effectiveness of …
advanced gastric cancer (GC). The current study evaluated the cost‐effectiveness of …